Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Heterogeneous nuclear ribonucleoprotein A1 pseudogene 35 (HNRNPA1P35) is a processed pseudogene, not a functional protein-coding gene. Unlike the functional HNRNPA1, which encodes an RNA-binding protein involved in pre-mRNA processing and cancer biology, HNRNPA1P35 is classified as a pseudogene and is not known to have biological activity or therapeutic relevance[1][3]. There is no current evidence to suggest that HNRNPA1P35 serves as a direct target for drugs, no known disease association, and no described biological function or mechanistic relevance. Key context: - HNRNPA1P35 is annotated as a processed pseudogene in genomic databases (e.g., Ensembl ENSG00000225695, HGNC:48764)[1][3]. - Pseudogenes do not produce functional proteins and generally do not serve as therapeutic targets. - Confusion may arise with the functional HNRNPA1 gene/protein, which is involved in RNA regulation and cancer, but HNRNPA1P35 specifically is a pseudogene and not a target of interest for drug development or biomarker studies[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Heterogeneous nuclear ribonucleoprotein A1 pseudogene 35 (HNRNPA1P35).